ATC/DDD classification - WHO

1 ATC/DDD classification WHO Drug Information Vol. 29, No. 4, 2015496 ATC/DDD classificationThe Anatomical Therapeutic Chemical (ATC) classification system and the Defined Daily Dose (DDD) as a measuring unit are tools for exchanging and comparing data on drug use at international, national or local levels. The ATC/DDD system has become the gold standard for international drug utilization research. It is maintained by the WHO Collaborating Centre for Drug Statistics Methodology in Oslo, Norway. Visit for more classification (temporary)The following ATC codes and DDDs were agreed at the meeting of the WHO International Working Group for Drug Statistics Methodology in October or objections to the decisions from the meeting should be forwarded to the WHO Collaborating Centre for Drug Statistics Methodology before 1 February 2016.

2 If no objections are received before this date, the new ATC codes and DDDs will be considered final and included in the January 2017 version of the ATC/DDD ATC 5th level codes:Please note that the list does not include new ATC codes established as a result of ATC level name/INNATC codeaceneuramic acidM09AX05alectinibL01XE36alirocumabC10 AX14aminobenzoate potassiumD11AX23arterolane and piperaquineP01BX02carvedilol and ivabradineC07FX06cobimetinibL01XE38darat umumabL01XC24deoxycholic acidD11AX24desfesoterodineG04BD13edoxaba nB01AF03elbasvir and grazoprevirJ05AX68elotuzumabL01XC23eluxa dolineA07DA06empegfilgrastimL03AA16etelc alcetideH05BX04ferric maltolB03AB10fluoroethyl-L-tyrosine

3 (18F)V09IX10follitropin deltaG03GA10/Continued 497 WHO Drug Information Vol. 29, No. 4, 2015 ATC/DDD classificationNew ATC 5th level codes, continuedATC level name/INNATC codegallium (68Ga) endotreotideV09IX09inotuzumab ozogamicinL01XC26ixekizumabL04AC13landio lolC07AB14metoprolol and ivabradineC07FX05metreleptinA16AA07mogam ulizumabL01XC25osimertinibL01XE35phenyle phrine and ketorolacS01FB51rociletinibL01XE37safina mideN04BD03salbutamol and beclometasoneR03AK13talimogene laherparepvecL01XX51tiazotic acidC01EB23tramadol and dexketoprofenN02AJ14trientineA16AX12 New ATC level codes (other than 5th levels).

4 ATC level nameATC codeBeta blocking agents, other combinationsC07 FXGlucagon-like peptide-1 receptor (GLP-1) analoguesA10 BJOpioids in combination with non-opioid analgesicsN02 AJSodium-glucose co-transporter 2 (SGLT2) inhibitorsA10 BKChange of ATC codes:ATC level name/INNP revious ATC codeNew ATC codealbiglutideA10BX13A10BJ04canaglifloz inA10BX11A10BK02dapagliflozinA10BX09A10B K01dulaglutideA10BX14A10BJ05empagliflozi nA10BX12A10BK03exenatideA10BX04A10BJ01li raglutideA10BX07A10BJ02lixisenatideA10BX 10A10BJ03mepolizumabL04AC06R03DX09methot rexate 1)L01BA01L04AX03 1)nonacog alfaB02BD09B02BD04 2)tioproninR05CB12G04BX16trenonacog alfaB02BD12B02BD04 2)1) Splitting of ATC code.

5 Only the classification of pre-filled syringes of methotrexate for use in non-cancer indications is changed. These products will be moved to the existing ATC code for oral administered product of methotrexate. Parenteral preparations used for treatment of cancer will remain in L01BA01. 2) Existing ATC code B02BD04 coagulation factor IXATC/DDD classification WHO Drug Information Vol. 29, No. 4, 2015498 Change of ATC level names:PreviousNewATC codeatenolol and other antihypertensivesatenolol and nifedipineC07FB03 Beta blocking agents and other antihypertensivesBeta blocking agents, other combinationsC07 FBeta blocking agents, selective, and other antihypertensivesBeta blocking agents and calcium channel blockersC07 FBbisoprolol and other antihypertensivesbisoprolol and amlodipineC07FB07nebivolol and other antihypertensivesnevibolol and amlodipineC07FB12oxycodone.

6 Combinationoxycodone and naloxoneN02AA55 Change of ATC code and/or ATC level name based on new ATC 4th levels establishedPrevious ATC code and level nameNew ATC code and/or level nameC07 FABeta blocking agents, non-selective, and other antihypertensivesDeletedC07 FXBeta blocking agents, other combinations C07FA05propranolol and other antihypertensivesC07FX01propranolol and other combinationsC07AA57sotalol, combinationsC07FX02sotalol and acetylsalicylic acidC07AB52metoprolol, combinationsC07FX03metoprolol and acetylsalicylic acidC07FB02 1) metoprolol and other antihypertensivesC07FB02 C07FB13metoprolol and felodipine 2)metoprolol and amlodipineC07AB57bisoprolol, combinationsC07FX04bisoprolol and acetylsalicylic acid N02 AJOpioids in combination with non-opioid analgesicsN02AA58 3) N02BE51 3)dihydrocodeine, combinations paracetamol, combinations excl.

7 PsycholepticsN02AJ01 4)dihydrocodeine and paracetamolN02AA58 3)N02BA51 3)dihydrocodeine, combinations acetylsalicylic acid, combinations excl. psycholepticsN02AJ02 4)dihydrocodeine and acetylsalicylic acidN02AA58 3)dihydrocodeine, combinationsN02AJ03 4)dihydrocodeine and other non-opioid analgesicsN02AA59 3) N02BE51 3)codeine, combinations excl. psycholepticsparacetamol, combinations excl. psycholepticsN02AJ06 4)codeine and paracetamol/Continued 499 WHO Drug Information Vol. 29, No. 4, 2015 ATC/DDD classificationChange of ATC code and/or ATC level name based on new ATC 4th levels established, continued/Previous ATC code and level nameNew ATC code and/or level nameN02AA59 3) N02BA51 3)codeine, combinations excl.

8 Psycholepticsacetylsalicylic acid, combinations excl. psycholepticsN02AJ07 4)codeine and acetylsalicylic acidN02AA59 3) M01AE51 3)codeine, combinations excl. psycholepticsibuprofen, combinationsN02AJ08 4)codeine and ibuprofenN02AA59 3)codeine, combinations excl. psycholepticsN02AJ09 4)codeine and other non-opioid analgesicsN02AX52tramadol, combinationsN02AJ13tramadol and paracetamolN02AA55 3) N02BE51 3)oxycodone, combinations 5)paracetamol, combinations excl. psycholepticsN02AJ17 4)oxycodone and paracetamolN02AA55 3)N02BA51 3)oxycodone, combinations 3)acetylsalicylic acid, combinations excl.

9 PsycholepticsN02AJ18 4)oxycodone and acetylsalicylic acidN02AA553)oxycodone, combinations 3)N02AJ19 4)oxycodone and ibuprofen1) Splitting of ATC code in connection with alterations in C07FX2) Existing ATC code3) Splitting of ATC codes according to contents of the different fixed combinations of opioids and other analgesics. The ATC codes in N02AA, N02BA51, N02BE51 and M01AE51 will be maintained for other ) Combinations with opioids and other analgesics currently classified in the following ATC codes N02AA55, N02AA58, N02AA59 will be moved to the new ATC 4th level N02AJ.

10 All the existing combination codes will be kept in N02AA since there may be other combinations without analgesics available ( oxycodone and naloxone will remain in N02AA55). The ATC classification of all low dose combinations products of codeine or dihydrocodeine (<20 mg dose) currently classified in N02B or M01A will be altered to the new ATC codes in ) Combinations of oxycodone and naloxone will be maintained in classification WHO Drug Information Vol. 29, No. 4, 2015500 New DDDs:ATC level *ATC alfa20mgPA16AB12evolocumab14mgPC10AX13fe rric degludec and liraglutide40U 1)PA10AE56mifepristone, 2) ,PJ01XX11* Administration Route: O=oral; P=parenteral1) Refers to insulin degludec 2) Refers to mifepristoneChange of DDD:ATC level name/INNP revious DDDNew DDDATC * *Blood coagulation factors1)Deleted 1) and enzyme inhibitor2g 2)P6g 2)PJ01CR01* Administration Route: O=oral.